LAMB1, short for laminin subunit beta 1, is a principal component of laminins, a family of large cross-shaped molecules that form a core part of the basement membrane, the specialized extracellular matrix layer that underlies and supports epithelial tissues. In healthy organs, laminins provide structural scaffolding, anchor cells in place, and transmit signals that regulate differentiation, adhesion, and migration. But over the past decade, cancer biologists have increasingly recognized that this same scaffold can be hijacked. Elevated LAMB1 levels have been linked to poor outcomes in gastric cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma, and a 2025 comprehensive review in the Journal of Translational Medicine catalogued the growing evidence that laminins actively shape cancer pathobiology rather than merely serving as passive architectural supports.

What remained unclear until now was LAMB1’s role in esophageal squamous cell carcinoma, a tumor type that arises from the flat epithelial cells lining the esophagus and that accounts for the majority of esophageal cancer cases worldwide. According to GLOBOCAN 2020 estimates cited by the researchers, the global burden of esophageal squamous cell carcinoma and esophageal adenocarcinoma remains substantial, with projections to 2040 indicating continued pressure on health systems, particularly in regions where the squamous form dominates. Despite advances in surgery, chemoradiotherapy, and, more recently, perioperative immunotherapy, five-year survival for many patients diagnosed with this disease remains discouraging, motivating a search for molecular markers that could guide earlier detection and more precise treatment.

To find such markers, the team began with bioinformatic screening of datasets from The Cancer Genome Atlas, cross-referencing tumor expression data with curated gene sets related to the extracellular matrix. Their computational sweep identified LAMB1 as a candidate gene associated with prognosis in esophageal squamous cell carcinoma. That prediction was then tested experimentally. Using quantitative polymerase chain reaction to measure messenger RNA, Western blotting to quantify protein, and immunohistochemistry to visualize where LAMB1 accumulates within tissue sections, the researchers demonstrated that LAMB1 expression was consistently elevated in esophageal squamous cell carcinoma tissues and in cell lines derived from the disease, compared with normal counterparts.

Expression, however, is only half the story; the critical question is whether LAMB1 actively drives malignancy or merely accompanies it. To answer this, the team performed gain- and loss-of-function experiments. When they forced LAMB1 overexpression in esophageal cancer cells, the cells became more aggressive: they proliferated faster, migrated more readily across experimental surfaces, and invaded more deeply through matrix-coated membranes in the laboratory assays. Conversely, when the researchers silenced LAMB1 using knockdown techniques, these malignant phenotypes were suppressed, with proliferation, migration, and invasion all dropping. The symmetry of the results, directionally consistent whether LAMB1 was added or removed, strengthens the causal interpretation that this matrix protein is not a bystander but an active promoter of tumor behavior.

The mechanistic heart of the study lies in the JAK2/STAT3 signaling cascade, a canonical communication channel inside cells. Janus kinases, or JAKs, are enzymes that attach phosphate groups to proteins, and when the JAK2 kinase is activated, it phosphorylates the STAT3 transcription factor. Phosphorylated STAT3 then travels to the nucleus, where it switches on genes that promote cell survival, cell-cycle progression, angiogenesis, metastasis, and resistance to chemotherapy. In esophageal squamous cell carcinoma specifically, prior research has shown that activated STAT3 can reduce patient survival by upregulating vascular endothelial growth factor and cyclin D1, and other studies have linked pathway activation to epithelial-mesenchymal transition, the process by which epithelial cancer cells acquire the motile, invasive characteristics needed to metastasize.

The new experiments connected LAMB1 to this cascade with unusual clarity. The researchers found that LAMB1 activates JAK2/STAT3 signaling by enhancing protein phosphorylation, effectively turning up the volume on the pathway. The proof of causation came from two independent interventions. First, the team treated the cells with ruxolitinib, a JAK1/2 inhibitor already approved for clinical use in certain blood disorders, and the drug efficiently abrogated the malignant phenotypes that LAMB1 had driven. Second, they silenced STAT3 directly with knockdown technology and observed the same reversal. In both cases, blocking the pathway erased the proliferative, migratory, and invasive advantages conferred by LAMB1, establishing that LAMB1 acts upstream and depends on JAK2/STAT3 to exert its tumor-promoting effects.

To confirm that the mechanism operates in living organisms and not only in culture dishes, the researchers turned to xenograft experiments, in which human cancer cells are implanted into laboratory animals under institutional ethical oversight. Tumors engineered with LAMB1 knockdown grew significantly less than controls, and molecular analysis of the resulting tumor tissue showed reduced activation of the JAK2/STAT3 pathway, mirroring the in vitro findings. The study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University and the institution’s animal care committee, and informed consent was obtained from all human participants, providing the governance framework that lends the results their clinical credibility.

The translational implications are twofold. As a biomarker, LAMB1’s elevated expression and its association with prognosis suggest that measuring it in tumor biopsies could help stratify patients, potentially identifying those with more aggressive disease who might benefit from intensified treatment or closer surveillance. As a therapeutic target, the ruxolitinib result is particularly intriguing because JAK inhibitors are already in clinical use, and the broader JAK2/STAT3 axis has attracted substantial pharmaceutical attention, with structural analysis and structure-activity relationship investigations fueling the development of pathway-targeting compounds. The study hints that esophageal cancer patients whose tumors are driven by LAMB1 might, in principle, respond to agents that interrupt this signaling route, although the researchers caution that much work remains before such a strategy could be tested in patients with this solid tumor.

There are also important caveats and open questions. The study did not receive external funding, and the authors declare no competing interests, but single-pathway mechanisms rarely explain a cancer’s full behavior, and LAMB1 has been implicated in other signaling routes, including the Hippo-YAP1 pathway in hepatocellular carcinoma and ERK/c-Jun signaling in gastric cancer, raising the possibility of parallel or interacting mechanisms in the esophagus as well. Moreover, how LAMB1 physically engages JAK2, whether through integrin receptors at the cell surface, mechanotransduction from matrix stiffness, or another route, remains to be dissected. Data supporting the study are available from the corresponding author upon reasonable request, and the corresponding author, Ziqiang Tian, led the supervision of the project. Still, by tracing a line from an extracellular scaffold protein through a druggable kinase cascade to the malignant behavior of one of the world’s most lethal cancers, the study adds a compelling new link in the chain that connects tumor architecture to tumor aggression, and it hands researchers a concrete new lead in a disease that badly needs one.

Subject of Research: The role of the extracellular matrix protein LAMB1 and the JAK2/STAT3 signaling pathway in the progression of esophageal squamous cell carcinoma

Article Title: LAMB1 accelerates esophageal squamous cell carcinoma by triggering JAK2/STAT3 signaling

Article References: Zhang, M., Liu, Z., Lv, H., Li, Z., Zhao, L., & Tian, Z. (2026). LAMB1 accelerates esophageal squamous cell carcinoma by triggering JAK2/STAT3 signaling. Molecular Biology Reports, 53(1), Article 1721. https://doi.org/10.1007/s11033-026-12853-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12853-0

Keywords: LAMB1, esophageal squamous cell carcinoma, JAK2/STAT3 signaling, extracellular matrix, laminin, ruxolitinib, STAT3 phosphorylation, xenograft, biomarker, cancer progression, phosphorylation, Molecular Biology Reports